LGM
VERV

Logos Global Management’s Verve Therapeutics VERV Stock Holding History

Logos Global Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-215,000
Closed -$2.85M – 71
2023
Q3 		$2.85M Buy
+215,000
New +$3.46M 0.38% 46
2022
Q2 		– Sell
-96,912
Closed -$2.21M – 42
2022
Q1 		$2.21M Sell
96,912
-346,353
-78% -$9.9M 0.29% 31
2021
Q4 		$16.3M Hold
443,265
– – 1.69% 19
2021
Q3 		$20.8M Sell
443,265
-315,000
-42% -$18.5M 1.5% 21
2021
Q2 		$45.7M Buy
+758,265
New +$31.5M 3.84% 4

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Logos Global Management's VERV Position: Q4 2023 in Review

Logos Global Management sold out of Verve Therapeutics (VERV) in Q4 2023, closing a stake of 215,000 shares — an estimated $2.85M sold.

Logos Global Management first reported a position in VERV in Q2 2021 and held it in 5 quarters. The position peaked at $45.7M in Q2 2021. 157 funds tracked by Wall St. Rank hold VERV as of Q4 2023.

  • Logos Global Management reported no remaining Verve Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Logos Global Management sold 215,000 Verve Therapeutics shares in Q4 2023, an estimated $2.85M.
  • Logos Global Management first reported a position in Verve Therapeutics in Q2 2021 and held it in 5 quarters.
  • Logos Global Management's Verve Therapeutics position peaked at $45.7M in Q2 2021.
  • 157 funds tracked by Wall St. Rank held Verve Therapeutics as of Q4 2023.

Based on Logos Global Management's 13F filing for Q4 2023, filed 14 Feb 2024.